Covid Vaccines and Intracellular RAS Pathway Activation

This research examines the potential activation of the intracellular Renin-Angiotensin System (RAS) pathway through ACE2 binding by Covid-19 vaccines, specifically AstraZeneca, Pfizer, and Moderna. The investigation focuses on identifying evidence of this pathway activation at the cellular level, encompassing both in vitro and in vivo studies. The study aims to understand the molecular interactions between vaccine-induced spike proteins and ACE2 receptors, assessing the extent of RAS pathway involvement. Key areas of interest include the biochemical signaling processes, phosphorylation events, and downstream effects resulting from ACE2 binding. This exploration includes examining the role of Angiotensin II, MAP kinases, and other intracellular mediators. Although the clinical implications are secondary, the research seeks to map out the cellular activation landscape, contributing to a better understanding of vaccine-induced molecular mechanisms. The study also considers variations across different cell types and experimental conditions to provide a comprehensive overview of the RAS pathway's engagement by Covid-19 vaccines.